Sherry Yang
Good morning, everyone. Welcome to day 3 of the JPM Healthcare Conference. My name is Sherry Yang, an associate in the Healthcare Investment Banking Group. And it’s my pleasure to be introducing Compass Therapeutics today. We have Tom Schuetz here, the CEO, with me on stage. Let’s give a warm welcome to Tom to the podium.
Thomas Schuetz
CEO & Vice Chairman
Thanks, Sherry, and thanks to JPMorgan for inviting us to present at the meeting this year. Just very briefly, I will be making forward-looking statements today, and I would refer you to our regulatory filings if you have any questions about those. Compass Therapeutics, we’re based in Boston, Mass. We’re a monoclonal antibody discovery and development company in oncology. We have 3 drugs in the clinic, and I’m going to talk about each of these drugs today because we’ve developed very important efficacy signals for each one of our drugs that’s in the clinic. And this quarter, our fourth drug is going to enter the clinic, and I’ll talk briefly about that drug as well.
This slide is a snapshot of our pipeline. Our most advanced program is Tovecimig. Tovecimig is a DLL4 VEGF-A bispecific antibody. That drug is a next-generation angiogenesis inhibitor. And recently, we announced that we hit the primary endpoint in a randomized study of Tovecimig in patients with advanced biliary tract cancer, and I’ll talk more about that study in detail.
Last week at ASCO GI, we presented data from a Phase II study in patients with very advanced colorectal cancer, and we have unequivocal monotherapy in patients with colorectal cancer
GIPHY App Key not set. Please check settings